Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences posts $516.5M 2025 net loss on $511M goodwill impairment

Mixed Impact 4 of 5 earnings Written later

Integra LifeSciences reported fourth-quarter 2025 revenue of $434.9 million, down 1.7%, with adjusted earnings of $0.83 per diluted share versus $0.97 a year earlier. Full-year 2025 GAAP net loss was $516.5 million, driven mainly by a $511 million non-cash goodwill impairment charge, while full-year adjusted earnings fell to $2.23 per share from $2.56. The company guided 2026 adjusted earnings to $2.30 to $2.40 per diluted share, which shareholders can compare against the 2025 result.

Key points

  • Q4 2025 revenue $434.9 million, down 1.7% reported and 2.5% organic; GAAP loss of $(0.02) per diluted share
  • Full-year 2025 revenue $1,635.2 million, up 1.5% reported; GAAP net loss $516.5 million, or $(6.74) per share
  • 2026 guidance: revenue $1,662 million to $1,702 million; adjusted EPS $2.30 to $2.40
  • Net debt about $1.6 billion at December 31, 2025; consolidated total leverage ratio 4.5x

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECFeb 26, 2026, 6:15 AM ET
Accession number0000917520-26-000008

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.